**Varilrix™**  
Varicella vaccine

**QUALITATIVE AND QUANTITATIVE COMPOSITION**

VARILRIX™ is a lyophilised preparation of the live attenuated Oka strain of varicella-zoster virus, obtained by propagation of the virus in MRC-5 human diploid cell culture.

VARILRIX™ meets the World Health Organisation requirements for biological substances and for varicella vaccines.

Each dose of the reconstituted vaccine contains not less than $10^{3.3}$ plaque-forming units (PFU) of the attenuated varicella-zoster virus.

The powder is slightly cream to yellowish or pinkish. The solvent is clear and colourless.

**PHARMACEUTICAL FORM**

Powder and solvent for solution for injection.

**CLINICAL PARTICULARS**

**Indications**

Healthy subjects

VARILRIX™ is indicated for active immunisation against varicella of healthy subjects from the age of 12 months onwards.

High-risk patients and healthy close contacts

VARILRIX™ is also indicated for active immunisation against varicella of susceptible high-risk patients and their susceptible healthy close contacts.

Patients with acute leukaemia

Patients suffering from leukaemia have been recognised to be at special risk when they develop varicella, and should receive vaccine if they have no history of the disease or are found to be seronegative.

When immunising patients in the acute phase of leukaemia, maintenance chemotherapy should be withheld one week before and one week after immunisation. Patients under radiotherapy should normally not be immunised during the treatment phase.

Patients under immunosuppressive treatment
Patients under immunosuppressive treatment (including corticosteroid therapy) for malignant solid tumour or for serious chronic diseases (such as chronic renal failure, auto-immune diseases, collagen diseases, severe bronchial asthma) are predisposed to severe varicella.

Generally patients are immunised when they are in complete haematological remission from the disease. It is advised that the total lymphocyte count should be at least 1,200 per mm$^3$ or no other evidence of lack of cellular immune competence exists.

*Patients with planned organ transplantation*

If organ transplantation (e.g. kidney transplant) is being considered, immunisation should be carried out a few weeks before the administration of the immunosuppressive treatment.

*Patients with chronic diseases*

Other chronic diseases, such as metabolic and endocrine disorders, chronic pulmonary and cardiovascular diseases, mucoviscidosis and neuromuscular abnormalities may also predispose to severe varicella.

*Healthy close contacts*

Susceptible healthy close contacts should be immunised in order to reduce the risk of transmission of virus to high-risk patients. These include parents and siblings of high-risk patients, and medical, paramedical personnel and other people who are in close contact with varicella patients or high-risk patients.

**Dosage and Administration**

0.5 ml of reconstituted vaccine contains one immunising dose.

**Posology**

*Healthy subjects*

- **Children 12 months up to and including 12 years of age**
  Children from the age of 12 months up to and including 12 years of age should receive 2 doses of VARILRIX$^\text{TM}$ to ensure optimal protection against varicella (*see Pharmacodynamics*).

  It is preferable to administer the second dose at least 6 weeks after the first dose but in no circumstances less than 4 weeks.

  [Note: Applicable official recommendations may vary regarding the interval between doses and the need for one or two doses of varicella-containing vaccines in children aged 12 months to 12 years].

- **Adolescents and adults from 13 years of age and above**
  From 13 years of age and above: 2 doses.
It is preferable to administer the second dose at least 6 weeks after the first dose but in no circumstances less than 4 weeks.

**High risk patients**

The same schedule described for healthy subjects should be applied for high-risk patients. In these patients, periodic measurement of varicella antibodies after vaccination may be indicated in order to identify those who may benefit from re-vaccination.

**Interchangeability**

- A single dose of VARILRIX™ may be administered to those who have already received a single dose of another varicella-containing vaccine.
- A single dose of VARILRIX™ may be administered followed by a single dose of another varicella-containing vaccine.

**Method of administration**

VARILRIX™ is for subcutaneous use only.

For information on instructions for preparation or reconstitution please refer to the “Instructions for Use/Handling” section.

**Contraindications**

As with other vaccines, the administration of VARILRIX™ should be postponed in subjects suffering from acute severe febrile illness. In healthy subjects the presence of a minor infection, however, is not a contra-indication for immunisation.

VARILRIX™ is contra-indicated in subjects with severe humoral or cellular immunodeficiency such as:

- subjects with primary or acquired immunodeficiency states with a total lymphocyte count less than 1,200 per mm$^3$;
- subjects presenting other evidence of lack of cellular immune competence, such as (e.g. subjects with leukaemias, lymphomas, blood dyscrasias, clinically manifest HIV infection);
- subjects receiving immunosuppressive therapy including high dose of corticosteroids.

See also “Warnings and Precautions”.

VARILRIX™ is contra-indicated in subjects with known hypersensitivity to neomycin, or to any other component of the vaccine, or to any other varicella vaccine.

VARILIX™ is contraindicated in subjects having shown signs of hypersensitivity after previous administration of varicella vaccine.

VARILRIX™ is contra-indicated in pregnant women. Pregnancy should be avoided for one month after vaccination (see Pregnancy and Lactation).
Warnings and Precautions

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Alcohol and other disinfecting agents must be allowed to evaporate from the skin before injection of the vaccine since they can inactivate the attenuated viruses in the vaccine.

As with any vaccine, a protective immune response may not be elicited in all vaccinees. As for other varicella vaccines, cases of varicella disease have been shown to occur in persons who have previously received VARILRIX™. These breakthrough cases are usually mild, with a fewer number of lesions and less fever as compared to cases in unvaccinated individuals.

Transmission of the Oka vaccine virus has been shown to occur at a very low rate in seronegative contacts of vaccinees with rash. Transmission of the Oka vaccine from a vaccinee who does not develop a rash to seronegative contacts cannot be excluded.

As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should remain under medical supervision for 30 minutes after immunisation.

There is limited data on the use of VARILIX™ in immunocompromised subjects, therefore vaccination should be considered with caution and only when, in the opinion of the physician, the benefits outweigh the risks.

Immunocompromised subjects who have no contraindication for this vaccination (see "Contraindications") may not respond as well as immunocompetent subjects, therefore some of these subjects may acquire varicella despite appropriate vaccine administration. Immunocompromised subjects should be monitored carefully for signs of varicella.

Very few reports exist on disseminated varicella with internal organ involvement following vaccination with Oka varicella vaccine strain mainly in immunocompromised subjects.

VARILRIX™ must not be administered intravascularly or intradermally.

Limited protection against varicella may be obtained by vaccination up to 72 hours after exposure to natural disease.

Serological studies of efficacy and post-marketing experience indicate that the vaccine does not completely protect all individuals from naturally-acquired varicella and cannot be expected to provide maximal protection against infection with varicella-zoster virus until about six weeks after the second dose.

Administration of VARILRIX™ to subjects who are in the incubation period of the infection cannot be expected to protect against clinically manifest varicella or to modify the course of the disease.
The rash produced during the naturally-acquired primary infection with varicella-zoster may be more severe in those with existing severe skin damage, including severe eczematous conditions. It is not known if there is an increase risk of vaccine-associated skin lesions in such persons, but this possibility should be taken into consideration before vaccination.

In healthy contacts of vaccinees, seroconversion has sometimes occurred in the absence of any clinical manifestations of infection. Clinically apparent infections due to transmission of the vaccine viral strain have been associated with few skin lesions and minimal systemic upset.

However, contact with the following groups must be avoided if the vaccinee develops a cutaneous rash thought likely to be vaccine-related (especially vesicular or papulovesicular) within four to six weeks of the first or second dose and until this rash has completely disappeared (see also sections on Pregnancy and Lactation and Pharmacological Properties).

- varicella-susceptible pregnant women and
- individuals at high risk of severe varicella, such as those with primary and acquired immunodeficiency states. These include individuals with leukaemia, lymphomas, blood dyscrasias, clinically manifest HIV infections, and patients who are receiving immunosuppressive therapy, including high dose corticosteroids.

In the absence of a rash in the vaccinee, the risk of transmission of the vaccine viral strain to contacts in the above groups appears to be extremely small. Nevertheless, vaccinees (e.g. healthcare workers) who are very likely to come into contact with persons in the above groups should preferentially avoid any such contact during the period between vaccinations and for 4-6 weeks after the second dose. If this is not feasible, then vaccinees should be vigilant regarding the reporting of any skin rash during this period, and should take steps as above if a rash is discovered.

**Interactions**

If tuberculin testing has to be done it should be carried out before or simultaneously with vaccination since it has been reported that live viral vaccines may cause a temporary depression of tuberculin skin sensitivity. As this anergy may last up to a maximum of 6 weeks, tuberculin testing should not be performed within that period after vaccination to avoid false negative results.

In subjects who have received immune globulins or a blood transfusion, immunisation should be delayed for at least three months because of the likelihood of vaccine failure due to passively acquired varicella antibodies.

Aspirin and systemic salicylates should not be given to children under the age of 16, except under medical supervision, because of the risk of Reye’s syndrome. Reye’s syndrome has been reported in children treated with aspirin during natural varicella infection.

**Healthy subjects**

VARILRIX™ can be administered at the same time as any other vaccines. Different injectable vaccines should always be administered at different injection sites. Inactivated vaccines can be administered in any temporal relationship to VARILRIX™.
Should a measles containing vaccine not be given at the same time as VARILRIX™, it is recommended that an interval of at least one month should be respected since it is recognised that measles vaccination may lead to short lived suppression of the cell mediated immune response.

**High-risk patients**

VARILRIX™ should not be administered at the same time as other live attenuated vaccines. Inactivated vaccines may be administered in any temporal relationship to VARILRIX™, given that no specific contra-indication has been established. Different injectable vaccines should always be administered at different injection sites.

**Pregnancy and Lactation**

**Pregnancy**

VARILRIX™ contains a live attenuated varicella-zoster virus. Pregnant women must not be vaccinated with VARILIX™. Pregnancy should be avoided for one month after vaccination. Women who intend to become pregnant should be advised to delay pregnancy.

Adequate human data on the use of VARILIX™ during pregnancy are not available and animal studies on reproductive toxicity have not been conducted.

Varicella-zoster virus may cause severe clinical disease in pregnant individuals and may adversely affect the foetus and/or result in perinatal varicella, depending on the gestational stage when the infection occurs. Because the possible effects of infection with the vaccine viral strain on the mother and on the foetus are unknown. VARILRIX™ must not be administered to pregnant women.

**Lactation**

It is not known whether VARILRIX™ is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VARILRIX™ is administered to a nursing woman.

**Effect on Ability to Drive and Use Machines**

It would not be expected that vaccination would affect the ability to drive or operate machinery.

**Adverse Reactions**

**Clinical trials**

**Healthy subjects**

More than 7,900 individuals have participated in clinical trials evaluating the reactogenicity profile of the vaccine administered alone or concomitantly with other vaccines.

The safety profile presented below is based on a total of 5369 doses of VARILRIX™ administered in monotherapy to children, adolescents and adults.
Frequencies are reported as:
Very common (≥1/10) /  
Common (≥1/100 to <1/10) /  
Uncommon (≥1/1,000 to <1/100) /  
Rare (≥1/10,000 to <1/1,000) /  
Very rare (<1/10,000)

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>Adverse reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Uncommon</td>
<td>Upper respiratory tract infection, pharyngitis</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Uncommon</td>
<td>Lymphadenopathy</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Uncommon</td>
<td>Irritability</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Uncommon</td>
<td>Headache, somnolence</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Rare</td>
<td>Conjunctivitis</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Uncommon</td>
<td>Cough, rhinitis</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Uncommon</td>
<td>Nausea, vomiting</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Abdominal pain, diarrhoea</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Common</td>
<td>Rash</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Varicella-like rash, pruritus</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>Urticaria</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Uncommon</td>
<td>Arthralgia, myalgia</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Very common</td>
<td>Pain, redness</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Swelling at the injection site*, fever (oral/axillary temperature ≥ 37.5°C or rectal temperature ≥ 38.0°C)*</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Fever (oral/axillary temperature &gt; 39.0°C or rectal temperature &gt; 39.5°C), fatigue, malaise</td>
</tr>
</tbody>
</table>

* Swelling at the injection site and fever were reported very commonly in studies conducted in adolescents and adults. Swelling was also reported very commonly after the second dose in children under 13 years of age.

A trend for higher incidence of pain, redness and swelling after the second dose was observed as compared to the first dose.

No difference was seen in the reactogenicity profile between initially seropositive and initially seronegative subjects.

**High-risk patients**

There are only very limited data from clinical trials available in patients at high risk of severe varicella. However, vaccine-associated reactions (principally papulo-vesicular eruptions and fever) are usually mild. As in healthy subjects, redness, swelling and pain at the site of injection are mild and transient.

**Post-marketing surveillance**
During post-marketing surveillance, the following additional reactions have been reported after varicella vaccination:

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>Adverse reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Rare</td>
<td>Herpes zoster</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Rare</td>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Rare</td>
<td>Hypersensitivity, anaphylactic reactions</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Rare</td>
<td>Encephalitis, cerebrovascular accident, cerebellitis, cerebellitis like symptoms (including transient gait disturbance and transient ataxia), convulsions</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Rare</td>
<td>Vasculitis (including Henoch Schönlein purpura and Kawasaki syndrome)</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rare</td>
<td>Erythema multiforme</td>
</tr>
</tbody>
</table>

**Overdose**

Cases of accidental administration of more than the recommended dose of VARILRIX™ have been reported. Amongst these cases, the following adverse events were reported: lethargy and convulsions. In the other cases reported as overdose there were no associated adverse events.

**PHARMACOLOGICAL PROPERTIES**

**Mechanism of action**

VARILRIX™ produces an attenuated clinically inapparent varicella infection in susceptible subjects.

**Pharmacodynamics**

ATC code J07B K01

The Oka strain virus contained in VARILRIX™ was initially obtained from a child with natural varicella; the virus was then attenuated through sequential passage in tissue culture.

Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity.

In clinical trials, the immune response to vaccination was routinely measured using an immunofluorescence assay. Antibody titres of $\geq 1:4$ (the detection level of the test) were considered as positive.

**Efficacy and effectiveness**

The efficacy of GlaxoSmithKline (GSK)'s monovalent Oka/RIT (VARILRIX™) and
Priorix-Tetra™ vaccines in preventing varicella disease has been evaluated in a large randomised clinical trial, which included GSK combined measles-mumps-rubella vaccine, Priorix as control. The trial has been conducted in European countries where no routine varicella vaccination is implemented.

Children aged 12-22 months received two doses of Priorix-Tetra six weeks apart (N = 2279) or one dose of VARILRIX™ (N = 2263) and were followed up for a period of approximately 35 months post vaccination (long term 10-year follow-up ongoing).

The observed vaccine efficacy against epidemiologically confirmed or PCR (Polymerase Chain Reaction) confirmed Varicella of any severity (defined using a prespecified scale) was 94.9% (97.5% CI: 92.4; 96.6%) after two doses of Priorix-Tetra and 65.4% (97.5% CI: 57.2; 72.1%) after one dose of VARILRIX™. Vaccine efficacy against moderate or severe confirmed varicella was 99.5% (97.5% CI: 97.5; 99.9%) after two doses of Priorix-Tetra and 90.7% (97.5% CI: 85.9; 93.9%) after one dose of VARILRIX™.

In a study in Finland specifically designed to evaluate vaccine efficacy of VARILRIX™, 493 children 10 to 30-month-old were followed up for a period of approximately 2.5 years after vaccination with one dose. The protective efficacy was 100% (95% CI: 80; 100%) against common or severe clinical cases of varicella (≥ 30 vesicles) and 88% (95% CI: 72; 96) against any serological confirmed case of varicella (at least 1 vesicle or papule).

The effectiveness of one dose of VARILRIX™ was estimated in different settings (outbreaks, case-control and database studies) and ranged from 20%-92% against any varicella disease and from 86%-100% against moderate or severe disease.

The impact of one dose of VARILRIX™ in reducing varicella hospitalizations and ambulatory visits among children were respectively 81% and 87% overall.

Effectiveness data suggest a higher level of protection and a decrease in breakthrough varicella following two doses of vaccine than following one dose.

In clinical trials that enrolled 211 adolescents and 213 adults, all vaccinees had detectable levels of antibodies in blood samples taken six weeks after the second vaccine dose. Virtually all (98.7%) of the 1637 children tested had detectable antibodies six weeks after immunisation with one dose of vaccine.

Virtually all (≥98.7%) children aged 9 months to 12 years tested had antibody levels ≥ 4 (dil-1) six weeks after immunisation with one dose of VARILRIX™.

All of 659 children aged 9 months to 6 years, who received a second dose of VARILRIX™ or received VARILRIX™ after a first dose of another varicella vaccine, had antibody levels ≥ 4 (dil-1) at 6-18 weeks following vaccination. There was a large increase in GMT (up to 13-fold) between post-dose 1 and post-dose 2.

However, the safety and immunogenicity of a second dose of VARILRIX™ in adolescents (≥13 years) and adults primed with another varicella-containing vaccine has not been specifically studied in clinical trials.

In a follow-up study over 2 years in 159 vaccinated adult health care workers, 2 out of 72 (3%) vaccinees reporting contacts with wild-type chickenpox experienced mild breakthrough disease. Approximately one-third of the vaccinees showed an increase in
antibody titre over the follow-up period, indicative of contact with the virus, without clinical evidence of varicella infection.

The percentage of vaccinees who will later experience herpes-zoster due to reactivation of the Oka strain virus is currently unknown. However, the risk of zoster after vaccination is currently thought to be much lower than would be expected after wild-type virus infection, due to attenuation of the vaccine strain.

**Pharmacokinetics**

Evaluation of pharmacokinetic properties is not required for vaccines.

**Clinical Studies**

See section “Pharmacodynamics”

**Pre-clinical Safety Data**

Non-clinical data reveal no special hazard for humans based on general safety tests performed in animals.

**PHARMACEUTICAL PARTICULARS**

**List of Excipients**

Excipients of the vaccine are: amino acids, human albumin, lactose, mannitol, sorbitol. Solvent is water for injections. Neomycin sulphate is present as a residual from the manufacturing process.

**Incompatibilities**

VARILRIX™ should not be mixed with other vaccines in the same syringe.

**Shelf Life**

The expiry date of the vaccine is indicated on the label and packaging.

It has been demonstrated that the reconstituted vaccine may be kept for up to 90 minutes at room temperature (25°C) and up to 8 hours in the refrigerator (2°C-8°C).

**Special Precautions for Storage**

The lyophilised vaccine should be stored in a refrigerator between +2°C and +8°C and protected from light. The solvent can be stored in the refrigerator or at ambient temperatures. The lyophilised vaccine is not affected by freezing.

When supplies of VARILRIX™ are distributed from a central cold store, it is necessary to arrange transport under refrigerator conditions.
After reconstitution, it is recommended that the vaccine be injected as soon as possible. (see *Shelf-Life*).

**Nature and Contents of Container**

VARILRIX™ is presented in a glass vial.

The sterile solvent is presented in ampoules and prefilled syringes.

**Instructions for Use/Handling**

Due to minor variations of its pH, the colour of the reconstituted vaccine may vary from clear peach to pink coloured solution.

Vaccines should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

Instructions for reconstitution of the vaccine with solvent presented in ampoules

VARILRIX™ must be reconstituted by adding the entire contents of the supplied ampoule of solvent to the vial containing the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent. After reconstitution, the vaccine should be used promptly.

A new needle should be used to administer the vaccine.

Withdraw the entire contents of the vial.

Instructions for reconstitution of the vaccine with solvent presented in pre-filled syringe

VARILRIX™ must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder. 

To attach the needle to the syringe, refer to the below drawing. However, the syringe provided with VARILRIX™ might be slightly different than the syringe described in the drawing.
1. Holding the syringe **barrel** in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
2. To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock. (see picture)
3. Remove the needle protector, which on occasion can be a little stiff.

Add the solvent to the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent. After reconstitution, the vaccine should be used promptly.

A new needle should be used to administer the vaccine.

Withdraw the entire contents of the vial

Any unused product or waste material should be disposed of in accordance with local requirements.

Not all presentations are available in every country.

Varilrix is a trademark of the GlaxoSmithKline group of companies.

Version number: GDS11/IPI012
Date of issue: 11/April/2014
© 2014 GlaxoSmithKline Group of Companies

Manufacturer
GlaxoSmithKline Biologicals s.a. Rue de l’Institut 89, B-1330 Rixensart, Belgium

[GSK Logo]